GC Green Cross and Aquitas Therapeutics Sign Contract to Introduce LNP Delivery System

[Asia Economy Reporter Chunhee Lee] GC Green Cross announced on the 28th that it has signed a development and option agreement to introduce lipid nanoparticle (LNP) technology owned by Aquitas Therapeutics, a Canadian company specializing in LNP delivery system development.

Under this agreement, GC Green Cross will be able to use up to four LNP technologies owned by Aquitas for the development of messenger ribonucleic acid (mRNA) vaccines or therapeutics.

LNP is a delivery system that injects mRNA into the body as nanoparticles. It is a core technology that enables the development of mRNA-based drugs. Aquitas Therapeutics' LNP technology has also been applied to Pfizer's COVID-19 vaccine.

This agreement is expected to give momentum to GC Green Cross's mRNA-related research, which has been ongoing since 2017. GC Green Cross is also making efforts to create synergy by integrating AI platforms into the development of mRNA rare disease therapeutics, such as recently signing a joint research agreement with Seoul National University AI Institute.

Thomas Madden, CEO of Aquitas Therapeutics, said, "I believe mRNA-based drugs will greatly contribute to improving human health," and added, "We are pleased to collaborate with GC Green Cross in developing new vaccines and therapeutics." Heun-chul Hur, CEO of GC Green Cross, also stated, "We continue efforts to apply various modalities in new drug development, including flu vaccines and rare disease therapeutics."

This content was produced with the assistance of AI translation services.